• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高CBD大麻提取物通过miRNA介导的沉默作用抑制人小肠上皮细胞中促炎因子的表达。

High-CBD cannabis extracts inhibit the expression of proinflammatory factors via miRNA-mediated silencing in human small intestinal epithelial cells.

作者信息

Wang Bo, Li Dongping, Fiselier Anna, Kovalchuk Igor, Kovalchuk Olga

机构信息

Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, T1K 3M4, Canada.

Pathway Rx Inc., Calgary, Alberta, T3H 4Z2, Canada.

出版信息

Heliyon. 2023 Aug 5;9(8):e18817. doi: 10.1016/j.heliyon.2023.e18817. eCollection 2023 Aug.

DOI:10.1016/j.heliyon.2023.e18817
PMID:37664748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10468390/
Abstract

The incidence of chronic inflammatory disorders and autoimmune diseases is rapidly growing. To date, the COVID-19 pandemic caused by SARS-CoV-2 has killed over 6,209,000 people globally, while no drug has been proven effective for the disease. Screening natural anti-inflammatory compounds for clinical application has drawn much attention. In this study, we showed that high-CBD cannabis extracts #1, #5, #7, #169, and #317 suppressed the levels of expression of proinflammatory cyclooxygenase 2 (COX2) and increased the expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human small intestinal epithelial cells (HSIEC) in TNFα/IFNγ-triggered inflammation. We revealed that these extracts, with the exception of extract #169, also profoundly attenuated induction of proinflammatory cytokines interleukin-6 (IL-6) and/or IL-8 proteins through miR-760- and miR-302c-3p-mediated silencing. The prevalent components in extracts #1 and #7 influenced the levels of IL-8 both individually as well as in combination with each other. However, the high-dose cannabis extracts displayed an inhibitory effect in the growth of HSIEC cells. These results show that our high-CBD cannabis extracts decrease the levels of proinflammatory molecules COX2, IL-6, and IL-8 via transcriptional suppression or miRNA-mediated silencing, highlighting their potential against COVID-19-associated cytokine storm syndrome.

摘要

慢性炎症性疾病和自身免疫性疾病的发病率正在迅速上升。截至目前,由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的新冠疫情已在全球造成超过620.9万人死亡,而尚无药物被证明对该疾病有效。筛选用于临床的天然抗炎化合物备受关注。在本研究中,我们发现高CBD大麻提取物#1、#5、#7、#169和#317在肿瘤坏死因子α/干扰素γ引发的炎症中,可抑制人小肠上皮细胞(HSIEC)中促炎环氧化酶2(COX2)的表达水平,并增加抗炎细胞因子信号传导抑制因子3(SOCS3)的表达。我们还发现,除提取物#169外,这些提取物还通过miR-760和miR-302c-3p介导的沉默作用,显著减弱促炎细胞因子白细胞介素-6(IL-6)和/或白细胞介素-8蛋白的诱导。提取物#1和#7中的主要成分单独或相互组合均会影响IL-8水平。然而,高剂量大麻提取物对HSIEC细胞的生长具有抑制作用。这些结果表明,我们的高CBD大麻提取物通过转录抑制或miRNA介导的沉默作用降低了促炎分子COX2、IL-6和IL-8的水平,凸显了它们对抗新冠相关细胞因子风暴综合征的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce12/10468390/66a58e56e3b1/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce12/10468390/b44e63b73eb1/gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce12/10468390/1994c410748e/gr2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce12/10468390/2cee85a54e19/gr3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce12/10468390/66a58e56e3b1/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce12/10468390/b44e63b73eb1/gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce12/10468390/1994c410748e/gr2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce12/10468390/2cee85a54e19/gr3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce12/10468390/66a58e56e3b1/gr4.jpg

相似文献

1
High-CBD cannabis extracts inhibit the expression of proinflammatory factors via miRNA-mediated silencing in human small intestinal epithelial cells.高CBD大麻提取物通过miRNA介导的沉默作用抑制人小肠上皮细胞中促炎因子的表达。
Heliyon. 2023 Aug 5;9(8):e18817. doi: 10.1016/j.heliyon.2023.e18817. eCollection 2023 Aug.
2
New AKT-dependent mechanisms of anti-COVID-19 action of high-CBD Cannabis sativa extracts.高CBD含量大麻提取物抗COVID-19作用的新的依赖AKT的机制
Cell Death Discov. 2022 Mar 11;8(1):110. doi: 10.1038/s41420-022-00876-y.
3
Fighting the storm: could novel anti-TNFα and anti-IL-6 cultivars tame cytokine storm in COVID-19?抗击风暴:新型抗 TNF-α 和抗 IL-6 制剂能否控制 COVID-19 中的细胞因子风暴?
Aging (Albany NY). 2021 Jan 19;13(2):1571-1590. doi: 10.18632/aging.202500.
4
High-CBD Extract (CBD-X) Downregulates Cytokine Storm Systemically and Locally in Inflamed Lungs.高 CBD 提取物(CBD-X)全身性和局部下调肺部炎症中的细胞因子风暴。
Front Immunol. 2022 May 16;13:875546. doi: 10.3389/fimmu.2022.875546. eCollection 2022.
5
In search of preventive strategies: novel high-CBD extracts modulate ACE2 expression in COVID-19 gateway tissues.寻找预防策略:新型高CBD提取物调节新冠病毒感染关键组织中的ACE2表达。
Aging (Albany NY). 2020 Nov 22;12(22):22425-22444. doi: 10.18632/aging.202225.
6
Cannabinoids Alleviate the LPS-Induced Cytokine Storm via Attenuating NLRP3 Inflammasome Signaling and TYK2-Mediated STAT3 Signaling Pathways In Vitro.大麻素通过抑制 NLRP3 炎性小体信号通路和 TYK2 介导的 STAT3 信号通路减轻 LPS 诱导的细胞因子风暴。
Cells. 2022 Apr 20;11(9):1391. doi: 10.3390/cells11091391.
7
The Anti-Inflammatory Effects of Extracts on LPS-Induced Cytokines Release in Human Macrophages.姜黄提取物对脂多糖诱导的人巨噬细胞细胞因子释放的抗炎作用。
Molecules. 2023 Jun 25;28(13):4991. doi: 10.3390/molecules28134991.
8
Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Extracts.结肠模型中的抗炎活性源自与提取物中其他化合物相互作用的Δ9-四氢大麻酚酸。
Cannabis Cannabinoid Res. 2017 Jul 1;2(1):167-182. doi: 10.1089/can.2017.0027. eCollection 2017.
9
Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages.大麻化合物在体外表现出抗 COVID-19 相关肺上皮细胞炎症的抗炎活性和巨噬细胞中的促炎活性。
Sci Rep. 2021 Jan 14;11(1):1462. doi: 10.1038/s41598-021-81049-2.
10
Analysis of Anti-Cancer and Anti-Inflammatory Properties of 25 High-THC Cannabis Extracts.分析 25 种高 THC 大麻提取物的抗癌和抗炎特性。
Molecules. 2022 Sep 16;27(18):6057. doi: 10.3390/molecules27186057.

引用本文的文献

1
Unveiling the Antioxidant Role of Hemp Oils in Cancer Prevention and Treatment.揭示大麻油在癌症预防和治疗中的抗氧化作用。
Cancers (Basel). 2025 Jun 25;17(13):2128. doi: 10.3390/cancers17132128.
2
Cannabidiol may prevent the development of congestive hepatopathy secondary to right ventricular hypertrophy associated with pulmonary hypertension in rats.大麻二酚可能预防大鼠中继发于与肺动脉高压相关的右心室肥大的充血性肝病的发展。
Pharmacol Rep. 2024 Apr;76(2):424-434. doi: 10.1007/s43440-024-00579-4. Epub 2024 Mar 22.

本文引用的文献

1
New AKT-dependent mechanisms of anti-COVID-19 action of high-CBD Cannabis sativa extracts.高CBD含量大麻提取物抗COVID-19作用的新的依赖AKT的机制
Cell Death Discov. 2022 Mar 11;8(1):110. doi: 10.1038/s41420-022-00876-y.
2
Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.托珠单抗治疗 COVID-19 肺炎住院患者:随机对照试验的系统评价和荟萃分析。
J Investig Med. 2022 Jan;70(1):55-60. doi: 10.1136/jim-2021-002001. Epub 2021 Sep 24.
3
Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
托珠单抗治疗重症 COVID-19 的获益和危害:系统评价和荟萃分析。
Pharmacotherapy. 2021 Nov;41(11):884-906. doi: 10.1002/phar.2627. Epub 2021 Oct 1.
4
Systemic corticosteroids for the treatment of COVID-19.全身性皮质类固醇治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD014963. doi: 10.1002/14651858.CD014963.
5
Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases.大麻素介导的炎症衰减的表观遗传调控及其对大麻素治疗自身免疫性疾病的影响。
Int J Mol Sci. 2021 Jul 7;22(14):7302. doi: 10.3390/ijms22147302.
6
Gastrointestinal Manifestations of COVID-19: A Review of What We Know.新型冠状病毒肺炎的胃肠道表现:我们所知的综述
Ochsner J. 2021 Summer;21(2):177-180. doi: 10.31486/toj.20.0086.
7
Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm.白细胞介素-6:新冠病毒细胞因子风暴的元凶
Indian J Clin Biochem. 2021 Oct;36(4):440-450. doi: 10.1007/s12291-021-00989-8. Epub 2021 Jun 21.
8
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial.COVID-19 住院患者使用托珠单抗的疗效:CORIMUNO-TOCI-1 随机临床试验的随访。
JAMA Intern Med. 2021 Sep 1;181(9):1241-1243. doi: 10.1001/jamainternmed.2021.2209.
9
Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis.托珠单抗治疗重症和危重症 COVID-19 的最佳应用:系统评价和荟萃分析。
F1000Res. 2021 Feb 4;10:73. doi: 10.12688/f1000research.45046.1. eCollection 2021.
10
Interleukin-6 blocking agents for treating COVID-19: a living systematic review.白细胞介素 6 阻断剂治疗 COVID-19:一项实时系统评价。
Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD013881. doi: 10.1002/14651858.CD013881.